Interestingly, melatonin, which has been shown by us to inhibit constitutively active NF-κB in prostate cancer cells via the membrane G protein-coupled MT1 receptor [23], reduces both AR-V7-induced NF-κB activation and IL-6 gene transcription in LNCaP and 22Rv1 cells (Figure 5 and Figure 7). The gene discussed is NFKB1; the disease is prostate cancer.